Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma

ABSTRACT:

Simple Summary

Survival of patients with multiple myeloma continues to improve over time in parallel with the development of new treatments. The combination of novel agents in the first-line setting appears to be the main factor driving improvement, resulting in overall survival (OS) of more than 12 and 8 years in patients aged ≤ 70 and >70 years, respectively. In addition, different baseline characteristics have been identified that favorably affected the probability of long-term survival (≥10 years) compared with early death (≤2 years). Therefore, we could conclude that multiple myeloma has become a chronic and even curable disease, in a subset of patients with the current therapeutic approaches.

Abstract

(1) Background: New therapeutic strategies have improved the prog

SUBMITTER: Puertas B 

PROVIDER: S-EPMC10000382 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature